Business Context and Reporting Period
Company: NeoStem, Inc. (Note: Metadata listed "Lisata Therapeutics," but filing text confirms registrant is NeoStem, Inc.)
Reporting Period: Quarter ended March 31, 2009
Business Overview: NeoStem operates a commercial autologous adult stem cell bank and is developing regenerative medicine technologies, including VSEL (very small embryonic-like) stem cells. The company manages a network of collection centers in the U.S. and is pursuing expansion into China through strategic mergers and licensing agreements.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $45,138 | $693 |
| Gross Profit | $21,588 | $693 |
| Operating Loss | $(1,856,948) | $(2,523,638) |
| Net Loss | $(1,867,243) | $(2,527,199) |
| Net Loss Per Share (Basic/Diluted) | $(0.24) | $(0.52) |
| Cash and Cash Equivalents (End of Period) | $392,791 | $969,776 |
| Working Capital | $(2,074,118) | Not explicitly stated |
| Total Current Liabilities | $2,615,292 | $961,140 |
| Stockholders' Equity (Deficit) | $(804,423) | $863,176 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $693 in Q1 2008 to $45,138 in Q1 2009, driven by stem cell collection fees and storage fees.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by approximately $645,800 (26%) to $1.88 million. This reduction was primarily due to a decrease in the use of equity instruments (stock and warrants) to pay for services, which dropped by roughly $1.09 million compared to the prior year.
- Net Loss Improvement: Net loss narrowed by approximately $660,000 to $1.87 million, reflecting the reduction in non-cash equity compensation expenses.
- Liquidity Deterioration: Cash balances declined from $430,786 at the start of the period to $392,791. Current liabilities surged to $2.6 million, largely due to the issuance of $1.15 million in promissory notes to a related party (RimAsia Capital Partners) in February and March 2009.
- Equity Position: The company moved from positive stockholders' equity of $863,176 at year-end 2008 to a deficit of $(804,423) by March 31, 2009.
Guidance, Outlook, and Risks
- Financing and Liquidity: The company completed an $11 million private placement in April 2009 (subsequent to the period end) to fund operations and repay the $1.15 million bridge notes. Management states that additional capital will be required to fund expansion in the U.S. and China and to develop VSEL technology.
- Strategic Initiatives: NeoStem is pursuing a merger with China Biopharmaceuticals Holdings, Inc. (CBH) and a share exchange with Shandong New Medicine Research Institute to acquire revenue-generating businesses in China. These transactions are anticipated to close in the third quarter of 2009, subject to shareholder approval.
- Operational Changes: The company outsourced its U.S. cryopreservation operations to Progenitor Cell Therapy LLC to convert fixed costs to variable costs and is closing its Los Angeles laboratory.
- Risks: Significant risks include the company's history of losses, negative working capital, dependence on future financing, the uncertainty of closing the proposed China transactions, and the need for regulatory approvals for its stem cell therapies.
Investor Verification Checklist
- Debt Repayment: Verify the repayment of the $1.15 million RimAsia notes and the terms of the $11 million Series D Preferred Stock financing completed in April 2009.
- Merger Status: Confirm the status of the proposed merger with China Biopharmaceuticals Holdings, Inc. and the share exchange with Shandong New Medicine Research Institute, including shareholder approval requirements.
- Equity Dilution: Review the impact of the Series D Preferred Stock (convertible to common stock) and the extensive warrant and option grants on future share count and dilution.
- Revenue Sustainability: Assess the sustainability of the revenue growth from stem cell collection fees and the timeline for commercialization of VSEL and other regenerative technologies.
- Related Party Transactions: Scrutinize the terms of the notes payable to RimAsia (a principal stockholder) and the reimbursement of expenses advanced by RimAsia for China expansion.